LTRN — Lantern Pharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1763950 ·
Last close
$0.83
Market Cap
$10.61M
52W High
$4.69
52W Low
$0.83
ADV30
264,795
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,508,090 | -7,072,124 | 8,602,349 | 6,660,170 | 11,819,601 |
| Mar 2026 | 0 | — | -3,405,247 | -3,329,171 | 7,223,067 | 4,917,796 | 3,777,366 |
| Dec 2025 | 0 | — | -4,202,762 | -4,074,217 | 11,035,811 | 4,422,838 | 4,501,587 |
| Sep 2025 | 0 | — | -4,349,800 | -4,177,423 | 13,626,810 | 8,389,486 | 4,039,972 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,073,997
Investing CF
$12,067,742
Financing CF
$1,498,240
CapEx
$-4,798
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.51
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,474,226
Inventory
—
Receivables
—
ST Investments
$1,405,057
EBIT TTM
$-16,609,709
Pretax Income TTM
$-15,911,826
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -17,978,494 | -17,119,438 | 11,035,811 | 4,501,587 | 6,534,224 | -15,676,980 |
| Dec 2024 | 0 | -22,216,437 | -20,781,213 | 25,571,792 | 4,384,018 | 21,187,774 | -17,813,201 |
| Dec 2023 | 0 | -17,877,570 | -15,961,534 | 43,647,616 | 2,739,682 | 40,907,934 | -14,346,548 |
| Dec 2022 | 0 | -14,432,753 | -14,259,946 | 58,836,321 | 2,798,297 | 56,038,024 | -12,767,492 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-15,911,826
OpCashFlow TTM
—
Assets (Latest)
$7,223,067
Forward EPS
$-2.02
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.81 · call volume: 2 · put volume: 1
Expected Move to 2026-10-16:
±$2.27
(279.32%) —
implied range
$-1.46 –
$3.08
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BLRX | BioLineRx Ltd. | $10.72M | $2.21 | — |
| GTBP | GT Biopharma, Inc. | $10.75M | $5.96 | — |
| TOVX | Theriva Biologics, Inc. | $10.42M | $0.23 | — |
| LSTA | LISATA THERAPEUTICS, INC. | $10.81M | $1.20 | — |
| BIVI | BIOVIE INC. | $10.82M | $1.28 | — |
News headlines (Yahoo Finance, 1h cache)
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
2026-10-08 12:00 · Yahoo
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
2026-10-08 11:05 · Yahoo
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
2026-10-07 12:31 · Yahoo
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
2026-09-30 20:01 · Yahoo
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
2026-09-23 11:45 · Yahoo
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
2026-09-19 15:45 · Yahoo
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
2026-09-17 12:20 · Yahoo
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
2026-09-05 14:50 · Yahoo
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
2026-08-21 12:28 · Yahoo
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ...
2026-08-20 01:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.